Prostate Cancer Vaccines and Therapeutic Antibodies: Pipeline, 2011 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Prostate Cancer Vaccines and Therapeutic Antibodies: Pipeline, 2011

Description:

Aarkstore.com announce a new report "Prostate Cancer Vaccines and Therapeutic Antibodies: Pipeline, 2011" through its vast collection of market research report. – PowerPoint PPT presentation

Number of Views:98

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Prostate Cancer Vaccines and Therapeutic Antibodies: Pipeline, 2011


1
Aarkstore.com Prostate Cancer Vaccines and
Therapeutic Antibodies Pipeline, 2011
2
Summary
  • The prostate cancer immunotherapy pipeline is
    showing rapid development. Currently, there are
    30 candidates in the pipeline (16 vaccines and 14
    therapeutic antibodies), and one prostate cancer
    vaccine (Provenge) has recently been approved by
    the FDA. First-line treatments for prostate
    cancer are largely based on anti-androgen drugs,
    or pituitary down-regulators. Other treatments
    include surgery, radiotherapy and chemotherapy.
    Resistance is commonly seen in the case of
    androgen-targeting drugs. Other therapies such as
    surgery and radiotherapy may be effective, but
    present increased risk. These treatment
    limitations have prompted efforts to develop
    safer, targeted therapies. In April 2010,
    Dendreon Inc. received FDA approval for its
    vaccine, Provenge an autologous cellular
    immunotherapy developed for metastatic prostate
    cancer. This vaccine is based on the use of
    patients own peripheral blood mononuclear cells,
    following prior treatment with a Prostate Acid
    Phosphatase/Granulocyte-Macrophage
    Colony-Stimulating Factor (PAP/GM-CSF) fusion
    protein. PAP is a commonly expressed prostate
    cancer antigen. The development of new
    candidate vaccines and therapeutic antibodies to
    target prostate cancer, is showing rapid
    progress. There are 30 candidates in the pipeline
    (16 prostate cancer vaccines and 14 prostate
    cancer-targeting antibodies)

3
Table of Contents
  • Report ContentsExecutive SummaryChapter 1
    Background p.7 1. Prostate Cancer1.1
    Statistics1.2 Diagnosis1.3 Staging1.4 Current
    Treatments1.5 This ReportChapter 2 Prostate
    Cancer Immunotherapy Strategies p.12 2.1
    Vaccines AntibodiesChapter 3 Approved Vaccine
    p.18 Chapter 4 Phase III Vaccines and
    Antibodies p.23

4
More Related Reports
  •   VEGF Inhibition Therapy-Indicating and
    Prognostic Biomarkers, 2011
  •   Biomarkers in Alzheimers Disease, 2011
  •   Alzheimers Disease Autoantibodies, Vaccines
    and Therapeutic Antibodies Pipeline, 2011
  •   Prostate Cancer Vaccines and Therapeutic
    Antibodies Pipeline, 2011
  •   Breast Cancer Vaccines and Therapeutic
    Antibodies Pipeline, 2011
  •   Alzheimers Disease Biomarkers in Cerebrospinal
    Fluid and Blood, 2011
  •   Image-Based Biomarkers in Alzheimers Disease,
    2011
  •   Lung Cancer Vaccines and Therapeutic
    Antibodies Pipeline, Strategies and Clinical

5
For More details
  • http//www.aarkstore.com/reports/Prostate-Cancer-V
    accines-and-Therapeutic-Antibodies-Pipeline-2011-1
    46441.html
  • Vina
  • Aarkstore.com
  • Contact Marketing team
  • Mob.No.918149852585
  • Email enquiry_at_aarkstore.com
  • URL http//www.aarkstore.com/
  • XML http//www.aarkstore.com/feeds/Biopharmrepor
    ts.xml
About PowerShow.com